AU2020274564A1 - Crystalline forms of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide - Google Patents

Crystalline forms of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Download PDF

Info

Publication number
AU2020274564A1
AU2020274564A1 AU2020274564A AU2020274564A AU2020274564A1 AU 2020274564 A1 AU2020274564 A1 AU 2020274564A1 AU 2020274564 A AU2020274564 A AU 2020274564A AU 2020274564 A AU2020274564 A AU 2020274564A AU 2020274564 A1 AU2020274564 A1 AU 2020274564A1
Authority
AU
Australia
Prior art keywords
fluorocyclopropyl
oxadiazol
imidazo
methylphenyl
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020274564A
Other languages
English (en)
Inventor
Andreas Kordikowski
Xiaoyang Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2020274564A1 publication Critical patent/AU2020274564A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2020274564A 2019-05-13 2020-05-13 Crystalline forms of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Abandoned AU2020274564A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019086582 2019-05-13
CNPCT/CN2019/086582 2019-05-13
PCT/CN2020/090060 WO2020228746A1 (en) 2019-05-13 2020-05-13 Crystalline forms of n- (5- (5- ( (1r, 2s) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide

Publications (1)

Publication Number Publication Date
AU2020274564A1 true AU2020274564A1 (en) 2021-12-09

Family

ID=73289607

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020274564A Abandoned AU2020274564A1 (en) 2019-05-13 2020-05-13 Crystalline forms of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide

Country Status (14)

Country Link
US (1) US20220194936A1 (https=)
EP (1) EP3969453A4 (https=)
JP (1) JP2022533340A (https=)
KR (1) KR20220007650A (https=)
CN (1) CN114096538A (https=)
AU (1) AU2020274564A1 (https=)
BR (1) BR112021022685A2 (https=)
CA (1) CA3139552A1 (https=)
IL (1) IL287877A (https=)
MA (1) MA55976A (https=)
MX (1) MX2021013814A (https=)
SG (1) SG11202112281UA (https=)
TW (1) TW202108581A (https=)
WO (1) WO2020228746A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022016021A1 (en) * 2020-07-15 2022-01-20 Third Harmonic Bio, Inc. Crystalline forms of a selective c-kit kinase inhibitor
US20220175740A1 (en) * 2020-11-19 2022-06-09 Novartis Ag Pharmaceutical compositions of a selective c-kit kinase inhibitor and methods for making and using same
EP4247368A4 (en) * 2020-11-19 2024-10-23 Third Harmonic Bio, Inc. PHARMACEUTICAL COMPOSITIONS OF A SELECTIVE C-KIT KINASE INHIBITOR AND METHODS FOR THE PREPARATION AND USE THEREOF
IL321144A (en) 2022-11-30 2025-07-01 Blueprint Medicines Corp History of N-phenyl-pyrazolo[5,1-A]pyridine-3-carboxamide as wild-type C-KIT kinase inhibitors for the treatment of erectile dysfunction
TW202542157A (zh) * 2024-01-04 2025-11-01 大陸商上海翰森生物醫藥科技有限公司 多環類衍生物抑制劑、其製備方法和應用
WO2025256609A1 (en) * 2024-06-13 2025-12-18 Third Harmonic Bio, Inc. Crystalline forms of a selective c-kit kinase inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014525450A (ja) * 2011-09-01 2014-09-29 アイアールエム・リミテッド・ライアビリティ・カンパニー ｃ−Ｋｉｔキナーゼ阻害剤としての化合物および組成物
US9199981B2 (en) * 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
EA201490537A1 (ru) * 2011-09-01 2014-07-30 АйАрЭм ЭлЭлСи СОЕДИНЕНИЯ И КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ C-Kit
EP2751104B1 (en) * 2011-09-01 2019-09-25 Novartis AG Compounds and compositions as c-kit kinase inhibitors

Also Published As

Publication number Publication date
JP2022533340A (ja) 2022-07-22
BR112021022685A2 (pt) 2022-03-29
KR20220007650A (ko) 2022-01-18
CN114096538A (zh) 2022-02-25
WO2020228746A1 (en) 2020-11-19
SG11202112281UA (en) 2021-12-30
IL287877A (en) 2022-01-01
MX2021013814A (es) 2022-02-10
EP3969453A4 (en) 2023-01-18
EP3969453A1 (en) 2022-03-23
MA55976A (fr) 2022-03-23
US20220194936A1 (en) 2022-06-23
TW202108581A (zh) 2021-03-01
CA3139552A1 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
WO2020228746A1 (en) Crystalline forms of n- (5- (5- ( (1r, 2s) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide
US12384758B2 (en) Crystalline form of LNP023
EP3679017B1 (en) Co-crystal of an orally available hif prolyl hydroxylase inhibitor
JP2022534216A (ja) Ｂｔｋ阻害剤の結晶形態
EP3808742A1 (en) Polymorph of selinexor
EP3239138A1 (en) Hydrogen fumarate salt of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidine
US12590095B2 (en) Crystalline forms of an orally available, selective kit and PDGFR kinase inhibitor
EP3887356B1 (en) Multi-component crystals of an orally available hif prolyl hydroxylase inhibitor
US20240059661A1 (en) Solid state forms of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or its pharmaceutically acceptable salts and polymorphs thereof
KR102858471B1 (ko) Lta4h 저해제의 결정질 형태

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application